Recent Updates of Transarterial Chemoembolilzation in Hepatocellular Carcinoma
Transarterial chemoembolization (TACE) is a standard treatment for intermediate-stage hepatocellular carcinoma (HCC). In this review, we summarize recent updates on the use of TACE for HCC. TACE can be performed using two techniques; conventional TACE (cTACE) and drug-eluting beads using TACE (DEB-T...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2020-10-01
|
| Series: | International Journal of Molecular Sciences |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1422-0067/21/21/8165 |
| _version_ | 1797549142824714240 |
|---|---|
| author | Young Chang Soung Won Jeong Jae Young Jang Yong Jae Kim |
| author_facet | Young Chang Soung Won Jeong Jae Young Jang Yong Jae Kim |
| author_sort | Young Chang |
| collection | DOAJ |
| description | Transarterial chemoembolization (TACE) is a standard treatment for intermediate-stage hepatocellular carcinoma (HCC). In this review, we summarize recent updates on the use of TACE for HCC. TACE can be performed using two techniques; conventional TACE (cTACE) and drug-eluting beads using TACE (DEB-TACE). The anti-tumor effect of the two has been reported to be similar; however, DEB-TACE carries a higher risk of hepatic artery and biliary injuries and a relatively lower risk of post-procedural pain than cTACE. TACE can be used for early stage HCC if other curative treatments are not feasible or as a neoadjuvant treatment before liver transplantation. TACE can also be considered for selected patients with limited portal vein thrombosis and preserved liver function. When deciding to repeat TACE, the ART (Assessment for Retreatment with TACE) score and ABCR (AFP, BCLC, Child-Pugh, and Response) score can guide the decision process, and TACE refractoriness needs to be considered. Studies on the combination therapy of TACE with other treatment modalities, such as local ablation, radiation therapy, or systemic therapy, have been actively conducted and are still ongoing. Recently, new prognostic models, including analysis of the neutrophil-lymphocyte ratio, radiomics, and deep learning, have been developed to help predict survival after TACE. |
| first_indexed | 2024-03-10T15:10:32Z |
| format | Article |
| id | doaj.art-f6ee56541bad48d09037ddfd51148637 |
| institution | Directory Open Access Journal |
| issn | 1661-6596 1422-0067 |
| language | English |
| last_indexed | 2024-03-10T15:10:32Z |
| publishDate | 2020-10-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | International Journal of Molecular Sciences |
| spelling | doaj.art-f6ee56541bad48d09037ddfd511486372023-11-20T19:24:46ZengMDPI AGInternational Journal of Molecular Sciences1661-65961422-00672020-10-012121816510.3390/ijms21218165Recent Updates of Transarterial Chemoembolilzation in Hepatocellular CarcinomaYoung Chang0Soung Won Jeong1Jae Young Jang2Yong Jae Kim3Department of Internal Medicine, Digestive Disease Center, Institute for Digestive Research, Soonchunhyang University College of Medicine, Seoul 04401, KoreaDepartment of Internal Medicine, Digestive Disease Center, Institute for Digestive Research, Soonchunhyang University College of Medicine, Seoul 04401, KoreaDepartment of Internal Medicine, Digestive Disease Center, Institute for Digestive Research, Soonchunhyang University College of Medicine, Seoul 04401, KoreaDepartment of Radiology, Soonchunhyang University College of Medicine, Seoul 04401, KoreaTransarterial chemoembolization (TACE) is a standard treatment for intermediate-stage hepatocellular carcinoma (HCC). In this review, we summarize recent updates on the use of TACE for HCC. TACE can be performed using two techniques; conventional TACE (cTACE) and drug-eluting beads using TACE (DEB-TACE). The anti-tumor effect of the two has been reported to be similar; however, DEB-TACE carries a higher risk of hepatic artery and biliary injuries and a relatively lower risk of post-procedural pain than cTACE. TACE can be used for early stage HCC if other curative treatments are not feasible or as a neoadjuvant treatment before liver transplantation. TACE can also be considered for selected patients with limited portal vein thrombosis and preserved liver function. When deciding to repeat TACE, the ART (Assessment for Retreatment with TACE) score and ABCR (AFP, BCLC, Child-Pugh, and Response) score can guide the decision process, and TACE refractoriness needs to be considered. Studies on the combination therapy of TACE with other treatment modalities, such as local ablation, radiation therapy, or systemic therapy, have been actively conducted and are still ongoing. Recently, new prognostic models, including analysis of the neutrophil-lymphocyte ratio, radiomics, and deep learning, have been developed to help predict survival after TACE.https://www.mdpi.com/1422-0067/21/21/8165transarterial chemoembolizationhepatocellular carcinomarefractorinesscombination therapy |
| spellingShingle | Young Chang Soung Won Jeong Jae Young Jang Yong Jae Kim Recent Updates of Transarterial Chemoembolilzation in Hepatocellular Carcinoma International Journal of Molecular Sciences transarterial chemoembolization hepatocellular carcinoma refractoriness combination therapy |
| title | Recent Updates of Transarterial Chemoembolilzation in Hepatocellular Carcinoma |
| title_full | Recent Updates of Transarterial Chemoembolilzation in Hepatocellular Carcinoma |
| title_fullStr | Recent Updates of Transarterial Chemoembolilzation in Hepatocellular Carcinoma |
| title_full_unstemmed | Recent Updates of Transarterial Chemoembolilzation in Hepatocellular Carcinoma |
| title_short | Recent Updates of Transarterial Chemoembolilzation in Hepatocellular Carcinoma |
| title_sort | recent updates of transarterial chemoembolilzation in hepatocellular carcinoma |
| topic | transarterial chemoembolization hepatocellular carcinoma refractoriness combination therapy |
| url | https://www.mdpi.com/1422-0067/21/21/8165 |
| work_keys_str_mv | AT youngchang recentupdatesoftransarterialchemoembolilzationinhepatocellularcarcinoma AT soungwonjeong recentupdatesoftransarterialchemoembolilzationinhepatocellularcarcinoma AT jaeyoungjang recentupdatesoftransarterialchemoembolilzationinhepatocellularcarcinoma AT yongjaekim recentupdatesoftransarterialchemoembolilzationinhepatocellularcarcinoma |